- US-listed companies
- Blueprint Medicines Corp
- Income statement
Blueprint Medicines Corp【BPMC】Income statement
Market cap
$8.4B
P/E ratio
| 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 11 | 28 | 21 | 45 | 67 | 794 | 180 | 204 | 249 | 509 |
| Revenue growth (%) | - | |||||||||
| Cost of revenue | - | - | - | - | - | 0 | 18 | 18 | 9 | 20 |
| Research & development | 49 | 81 | 145 | 244 | 331 | 327 | 601 | 477 | 428 | 341 |
| Selling, general & administrative | - | - | - | - | - | 158 | 195 | 237 | 295 | 359 |
| Operating expenses | 63 | 100 | 173 | 292 | 428 | 485 | 822 | 742 | 736 | 721 |
| Income before tax | - | - | - | - | - | 315 | -641 | -552 | -506 | -66 |
| Pretax margin (%) | - | - | - | - | - | 39.7 | -356 | -270.7 | -202.9 | -12.9 |
| Provision for income taxes | - | - | - | - | - | 1 | 3 | 5 | 1 | 1 |
| Effective tax rate (%) | - | - | - | - | - | |||||
| Net income | -53 | -72 | -148 | -237 | -348 | 314 | -644 | -558 | -507 | -67 |
| Net income margin (%) | ||||||||||
| Earnings per share | - | - | - | - | - | 5.76 | -11.01 | -9.35 | -8.37 | -1.07 |
| Diluted EPS | - | - | - | - | - | 5.59 | -11.01 | -9.35 | -8.37 | -1.07 |